

**CLEOPATRA HOSPITAL COMPANY "S.A.E."  
AND ITS SUBSIDIARIES**

**LIMITED REVIEW REPORT AND THE INTERIM  
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE MONTHS PERIOD ENDED  
31 MARCH 2022**

# CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

## Interim condensed consolidated financial statements For the three months period ended 31 March 2022

---

<b>Index</b>	<b>Page</b>
Limited review report	1
Interim condensed consolidated statement of financial position	2
Interim condensed consolidated statement of profit or loss	3
Interim condensed consolidated statement of comprehensive income	4
Interim condensed consolidated statement of changes in equity	5
Interim condensed consolidated statement of cash flows	6
Notes to the interim condensed consolidated financial statements	7 – 23



## Limited Review Report on the Interim Financial Statements

To: **The Board of Directors of Cleopatra Hospital Company (S.A.E.)**

### Introduction

We conducted our limited review on the accompanying interim condensed consolidated financial position of Cleopatra Hospital Company (S.A.E.) and its subsidiaries (the "Group") as at 31 March 2022 and the related interim condensed consolidated statements of profit or loss, comprehensive income, changes in equity and cash flows for the three months period then ended. The management is responsible for the preparation and fair presentation of these interim condensed consolidated financial statements in accordance with the Egyptian Accounting Standard No. (30) "Interim Financial Reporting". Our responsibility is limited to express a conclusion on these interim condensed consolidated financial statements based on our limited review.

### Scope of the limited review

We conducted our limited review in accordance with the Egyptian Standard on Limited Review Engagements (2410), "Limited Review of Interim Financial Statements Performed by the Auditor of the Entity". A limited review of the interim condensed consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other limited review procedures. A limited review is substantially less in scope than an audit conducted in accordance with the Egyptian Standards on Auditing and consequently does not enable us to obtain an assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion on these interim condensed consolidated financial statements.

### Conclusion

Based on our limited review, nothing has come to our attention which causes us to believe that the accompanying interim condensed consolidated financial statements are not prepared, in all material respects in accordance with the Egyptian Accounting Standard No. (30) "Interim Financial Reporting".

  
Tamer Abdel Tawab  
Member of Egyptian Society of Accountants & Auditors  
Member of AICPA  
R.A.A. 17996  
F.R.A. 388



26 May 2022  
Cairo

CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

Interim condensed consolidated statement of financial position - At 31 March 2022

(All amounts in Egyptian Pounds)	Note	31 March 2022	31 December 2021
<b>Assets</b>			
<b>Non-current assets</b>			
Fixed assets	4	1,374,720,056	1,351,725,422
Right-of-use assets	5	167,600,627	174,691,615
Goodwill		369,263,334	369,263,334
Other intangible assets		55,735,072	56,252,393
Investments in associates		2,178,501	2,178,301
Paid under investments purchased		5,673,000	5,673,000
<b>Total non-current assets</b>		<b>1,975,170,590</b>	<b>1,959,784,065</b>
<b>Current assets</b>			
Inventories	6	57,444,563	51,301,188
Trade receivables	8	431,303,955	383,324,030
Due from related parties	9	802,149	530,300
Debtors and other debit balances	10	118,332,057	191,702,419
Financial assets at amortized cost - treasury bills	11	492,322,214	677,072,914
Cash on hands and at banks	12	215,565,333	168,906,593
<b>Total current assets</b>		<b>1,315,770,271</b>	<b>1,472,837,444</b>
<b>Total assets</b>		<b>3,290,940,861</b>	<b>3,432,621,509</b>
<b>Equity and liabilities</b>			
<b>Equity</b>			
Share capital		800,000,000	800,000,000
Treasury Shares	23	(234,816,315)	(4,152,742)
Retained earnings		1,365,978,203	1,269,995,272
Share based payment		12,434,912	8,289,941
Reserves		302,942,579	302,942,579
<b>Equity attributable to the Company's owners</b>		<b>2,246,539,379</b>	<b>2,377,075,050</b>
Non-controlling interests	13	127,181,486	120,742,065
<b>Total equity</b>		<b>2,373,720,865</b>	<b>2,497,817,115</b>
<b>Liabilities</b>			
<b>Non-current liabilities</b>			
Lease liabilities	14	168,649,746	172,715,165
Deferred tax liabilities	7	81,939,459	81,809,839
Purchased investment liability		35,215,000	31,760,000
<b>Total non-current liabilities</b>		<b>285,804,205</b>	<b>286,285,004</b>
<b>Current liabilities</b>			
Banks overdraft	15	-	60,627,560
Provisions		21,175,944	21,917,498
Trade payables and other credit balances	16	476,169,974	461,032,559
Lease liabilities	14	40,599,053	38,742,917
Current income tax liabilities		93,470,820	66,198,856
<b>Total current liabilities</b>		<b>631,415,791</b>	<b>648,519,390</b>
<b>Total liabilities</b>		<b>917,219,996</b>	<b>934,804,394</b>
<b>Total liabilities and equity</b>		<b>3,290,940,861</b>	<b>3,432,621,509</b>

- The accompanying notes from (1) to (24) are integral part of these interim condensed consolidated financial statements  
 - Limited review report is attached

Mr. Ahmed Adel Badreldin  
 Non Executive Chairman

Cairo at 26 May 2022

Dr. Ahmed Ezz Eldin Mahmoud  
 CEO & Managing Director

Mr. Ahmed Gamal  
 Group CFO



**CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES**

**Interim condensed consolidated statement of profit or loss  
For the three months period ended 31 March 2022**

(All amounts in Egyptian Pounds)	Note	31 March 2022	31 March 2021
Operating revenue	17	636,905,385	633,163,172
<b>Less:</b>			
Operating costs	18	<u>(414,954,341)</u>	<u>(391,965,771)</u>
<b>Gross profit</b>		<b>221,951,044</b>	<b>241,197,401</b>
<b>Add / (Less):</b>			
General and administrative expenses	19	(92,025,716)	(81,754,737)
Impairment of financial assets	20	(10,046,040)	(11,827,230)
Provisions		(4,447,900)	(9,635,875)
Other income		1,865,015	6,214,165
<b>Operating profit</b>		<b>117,296,403</b>	<b>144,193,724</b>
Costs of acquisition activates		(794,522)	(5,308,034)
Finance income		20,671,871	12,635,505
Finance expenses		<u>(7,349,817)</u>	<u>(6,034,003)</u>
<b>Profit for the period before income tax</b>		<b>129,823,935</b>	<b>145,487,192</b>
Current tax		(27,271,964)	(37,417,603)
Deferred tax		<u>(129,619)</u>	<u>(131,726)</u>
<b>Profit after income tax</b>		<b>102,422,352</b>	<b>107,937,863</b>
<b>Profit for:</b>			
Owners of the parent company		95,982,931	101,308,913
Non-controlling interests		<u>6,439,421</u>	<u>6,628,950</u>
<b>Profit after income tax</b>		<b>102,422,352</b>	<b>107,937,863</b>
<b>Earning per share (Basic / Diluted)</b>	21	<b>0.06</b>	<b>0.06</b>

- The accompanying notes from (1) to (24) are integral part of these interim condensed consolidated financial statements.

## CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

### Interim condensed consolidated statement of comprehensive income For the three months period ended 31 March 2022

(All amounts in Egyptian Pounds)	<u>31 March 2022</u>	<u>31 March 2021</u>
Profit for the period	102,422,352	107,937,863
Other comprehensive income	-	-
<b>Total comprehensive income for the period</b>	<b><u>102,422,352</u></b>	<b><u>107,937,863</u></b>
<b>Profit for:</b>		
Owners of the parent Company	95,982,931	101,308,913
Non-controlling interests	6,439,421	6,628,950
	<b><u>102,422,352</u></b>	<b><u>107,937,863</u></b>

- The accompanying notes from (1) to (24) are integral part of these interim condensed consolidated financial statements.

**CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES**

**Interim condensed consolidated statement of changes in equity  
For the three months period ended 31 March 2022**

(All amounts in Egyptian Pounds)

	Share capital	Reserves	Retained earnings	Treasury shares	Share based payment	Total Shareholders equity of the parent Company	Non-controlling interest	Total equity
<b>Balance at 1 January 2021</b>	800,000,000	281,336,162	984,874,111	-	-	2,066,210,273	107,725,535	2,173,935,808
Impact of new standards adoption	-	-	(44,851,637)	-	-	(44,851,637)	(9,002,829)	(53,854,466)
Comprehensive income for the period	-	-	101,308,913	-	-	101,308,913	6,628,950	107,937,863
<b>Balance at 31 March 2021</b>	<b>800,000,000</b>	<b>281,336,162</b>	<b>1,041,331,387</b>	<b>-</b>	<b>-</b>	<b>2,122,667,549</b>	<b>105,351,656</b>	<b>2,228,019,205</b>
<b>Balance at 1 January 2022</b>	800,000,000	302,942,579	1,269,995,272	(4,152,742)	8,289,941	2,377,075,050	120,742,065	2,497,817,115
Treasury shares	-	-	-	(230,663,573)	-	(230,663,573)	-	(230,663,573)
Employees stock ownership Plan	-	-	-	-	4,144,971	4,144,971	-	4,144,971
Comprehensive income for the period	-	-	95,982,931	-	-	95,982,931	6,439,421	102,422,352
<b>Balance at 31 March 2022</b>	<b>800,000,000</b>	<b>302,942,579</b>	<b>1,365,978,203</b>	<b>(234,816,315)</b>	<b>12,434,912</b>	<b>2,246,539,379</b>	<b>127,181,486</b>	<b>2,373,720,865</b>

- The accompanying notes from (1) to (24) are integral part of these interim condensed consolidated financial statements.

CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

Interim condensed consolidated statement of cash flows  
For the three months period ended 31 March 2022

(All amounts in Egyptian Pounds)			
	Note	31 March 2022	31 March 2021
<b>Cash flows from operating activities</b>			
Profit before tax		129,823,935	145,487,192
<b>Adjustments to reconcile net income to cash flows from operating activities</b>			
Fixed assets depreciation	4	31,546,107	27,006,042
Depreciation - Right of use assets	5	6,603,555	6,192,676
Gain on sale of fixed assets		(418,279)	(19,535)
Amortization of intangible assets		3,972,321	3,972,321
Impairment of inventories	6	19,859	(215,793)
Impairment of trade receivables	8	10,255,436	24,441,931
Impairment in the value of cash at banks	12	(209,396)	3,167,887
Provisions		4,447,900	9,635,875
Employee incentive plan	22	4,144,971	1,086,075
Interest and commissions - Credit facilities		570,641	612,708
Interest and commissions - Lease contracts		6,515,133	5,395,753
Interest payable		(17,693,854)	(12,635,505)
Gain from investment in associates		-	(250,717)
<b>Operating profits before changes in assets and liabilities</b>		<b>179,578,329</b>	<b>213,876,910</b>
<b>Changes in assets and liabilities</b>			
Change in inventories		(6,163,234)	586,189
Change in trade receivables		(38,181,779)	(46,700,060)
Change in due from related parties		(271,849)	-
Change in due to related parties		-	(517,407)
Change in debtors and other debit balances		(8,490,345)	15,761,393
Change in creditors and other credit balances		15,941,834	6,788,800
<b>Changes in working capital</b>		<b>142,412,956</b>	<b>189,795,825</b>
Impairment of financial assets - write off		(20,053,582)	-
Provisions used		(5,189,455)	(8,595,362)
Income tax paid		-	(32,896,981)
<b>Net cash flows generated from operating activities</b>		<b>117,169,919</b>	<b>148,303,482</b>
<b>Cash flows from investing activities</b>			
Payments for purchase of fixed assets		(21,713,361)	(19,832,819)
Payments for projects under construction		(33,258,220)	(22,796,820)
Prepayments for purchase of fixed assets		4,609,656	(5,728,145)
Proceeds from sale of fixed assets		849,121	12,478
Payments under investments purchased		-	(5,673,000)
Payments for investments in associates		(200)	-
Interest received		14,248,767	10,965,210
<b>Net cash flows used in investing activities</b>		<b>(35,264,237)</b>	<b>(43,053,096)</b>
<b>Cash flows from financing activities</b>			
Proceeds from banks overdraft		(60,627,560)	52,979,744
Payment for purchase of treasury shares		(149,967,435)	-
Dividends paid		-	(47,772)
Interest and commissions paid		(7,890,208)	(7,051,408)
Lease liabilities payments - Lease contracts		(1,721,850)	(20,869,928)
<b>Net cash flows (used in) generated from financing activities</b>		<b>(220,207,053)</b>	<b>25,010,636</b>
<b>Change in cash and cash equivalents during the period</b>		<b>(138,301,371)</b>	<b>130,261,022</b>
Cash and cash equivalents at the beginning of the period		847,525,002	550,517,584
<b>Cash and cash equivalents at the end of the period</b>	12	<b>709,223,631</b>	<b>680,778,606</b>

- The accompanying notes from (1) to (24) are integral part of these interim condensed consolidated



# CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

## Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

---

### 1. Introduction

Cleopatra Hospital Company "the Parent Company" (formerly Lasheen & Co.) was incorporated as a limited partnership on July 19, 1979.

The decision of the head of Investment Authority No. 4092 of 2005 was issued on 27 June 2005 authorising the conversion of the legal type of Cleopatra Hospital from a "limited partnership" into Cleopatra Hospital Company "S.A.E." in accordance with the provisions of Law No. (8) Of 1997 and Law No. (95) Of 1992. The Company is listed on the Egyptian Stock Exchange.

The purpose of the Company and its subsidiaries (together referred to as the "Group") is to establish a private hospital to provide modern and high-quality health and medical services and to provide medical care to inpatients. The company may have an interest or may participate in any way with companies or others that carry out business like its business in Egypt or abroad. The company may also acquire, merge or attach to these facilities.

The Company is located at 39, 41 Cleopatra Street, Heliopolis, Cairo.

Care Healthcare is the controlling shareholder in the company with a 37.87% shareholding.

These interim condensed consolidated financial statements have been approved for issuance by the Board of Directors of the Parent Company on 26 May 2022.

### 2. Basis of preparation

#### A. Statement of Compliance

This interim condensed consolidated financial statements for the three-month reporting period ended 31 March 2022 have been prepared in accordance with Egyptian Accounting Standard 30 "Interim Financial Reporting".

This interim condensed consolidated financial information does not include all the disclosures that would normally be disclosed in preparing the full annual financial statements. Therefore, this interim condensed consolidated financial information should be read with the annual consolidated financial statements of the Group on 31 December 2021.

The accounting policies used in preparing this interim condensed financial information are consistent with those used in preparing the annual financial statements for the fiscal year ending on 31 December 2021 and the fiscal periods Comparison.

## CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### Statement of Compliance (continued)

The interim condensed consolidated financial statements include the financial statements of the following subsidiaries:

	Country of incorporation	Percentage of ownership 31 March 2022	Percentage of ownership 31 December 2021
Al-Shorouk Hospital Company S.A.E.	Egypt	99.99%	99.99%
Nile Badrawi Hospital Company S.A.E.	Egypt	99.99%	99.99%
Cairo Specialised Hospital Company S.A.E.	Egypt	56,46%	56,46%
CHG for Medical Services Company S.A.E.	Egypt	20%	20%
		(preference shares)	(preference shares)
CHG Pharma for Pharmacies Management Company S.A.E.	Egypt	98%	98%
CHG for hospitals S.A.E.	Egypt	99.99%	99.99%
Bedaya El Gedida Company for Medical Centers and Hospitals S.A.E.	Egypt	99.99%	99.99%
CHG Sky hospitals S.A.E.	Egypt	99.99%	99.99%

#### B. Functional and presentation currency

Items included in the interim consolidated financial statements are measured using the currency of the primary economic environment in which the Group operates ('the functional currency'). The interim consolidated financial statements are presented in Egyptian Pounds (EGP), which is the Group's functional and presentation currency.

#### C. Use of estimates and judgements

The preparation of interim financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income, and expense. Actual results may differ from these estimates.

Significant judgments used by management in applying the group's accounting policies and the main sources of estimation uncertainty are the same as those disclosed in the latest consolidated financial statements and for the financial year ended 31 December 2021.

## CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

### Notes to the consolidated interim financial statements - For the three months period ended 31 March 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 3. Segment reporting

Business segments are reported in line with the reports provided internally to the senior management, which makes decisions related to resources allocation and evaluation of segments' performance in the Group. The senior management is represented in Group's executive management committee. The segment reports are provided to the Group based on each company, as each subsidiary is considered a separate business segment.

Below is a summary of each segment, which is presented for the period ended 31 March 2022 for each segment:

Statement of financial position	Cleopatra Hospital Company	Cairo Specialised Hospital	Nile Badrawi Hospital	Al Shorouk Hospital	CHG for Medical Services	CHG Pharma for Pharmacies management	CHG for Hospitals	Queens Hospitals	AI Kateb Hospitals	Medical Centers and Hospitals	CHG Sky Consolidation hospital.	Consolidation adjustment	Total	Bedaya El Gedida for	
														Medical Centers	Hospitals
Non-current assets	1,497,975,436	316,894,288	250,831,577	241,587,521	40,148,452	3,668,860	-	71,187,956	136,074,218	91,246,939	-	(674,444,657)	1,975,170,590		
Current assets	561,537,014	175,956,806	172,726,391	207,888,016	21,752,812	13,713,002	24,783,308	103,570,750	41,570,973	46,524,291	35,000,000	(89,253,092)	1,315,770,271		
<b>Total assets</b>	<b>2,059,512,450</b>	<b>492,851,094</b>	<b>423,557,968</b>	<b>449,475,537</b>	<b>61,901,264</b>	<b>17,381,862</b>	<b>24,783,308</b>	<b>174,758,706</b>	<b>177,645,191</b>	<b>137,771,230</b>	<b>35,000,000</b>	<b>(763,697,749)</b>	<b>3,290,940,861</b>		
Current liabilities	202,965,415	143,084,533	89,114,278	95,792,237	89,466,810	19,813,117	593,996	50,929,990	31,412,199	12,215,836	-	(103,972,620)	631,415,791		
Non-current liabilities	41,533,659	12,465,634	21,505,449	25,224,409	40,298,815	4,427,051	-	66,869,109	3,447,197	22,176,051	-	47,856,831	285,804,205		
<b>Total Liabilities</b>	<b>244,499,074</b>	<b>155,550,167</b>	<b>110,619,727</b>	<b>121,016,646</b>	<b>129,765,625</b>	<b>24,240,168</b>	<b>593,996</b>	<b>117,799,099</b>	<b>34,859,396</b>	<b>34,391,887</b>	<b>-</b>	<b>(56,115,789)</b>	<b>917,219,996</b>		
Statement of profit or loss:															
Operating revenue	250,884,230	118,535,304	88,397,389	103,467,101	20,625,565	11,124,413	-	30,221,642	6,192,403	15,512,376	-	(8,055,038)	636,905,385		
Operating costs	(138,240,663)	(82,223,466)	(66,570,094)	(72,142,470)	(16,087,323)	(10,546,904)	-	(15,416,023)	(12,037,701)	(8,976,244)	-	7,286,547	(414,954,341)		
<b>Gross profit</b>	<b>112,643,567</b>	<b>36,311,838</b>	<b>21,827,295</b>	<b>31,324,631</b>	<b>4,538,242</b>	<b>577,509</b>	<b>-</b>	<b>14,805,619</b>	<b>(5,845,298)</b>	<b>6,536,132</b>	<b>-</b>	<b>(768,491)</b>	<b>221,951,044</b>		
Other expenses and revenues	(43,194,941)	(21,645,643)	(15,801,688)	(18,238,717)	(4,410,735)	(538,268)	(194,993)	(3,889,326)	(3,214,261)	(7,989,485)	-	(410,635)	(119,528,692)		
<b>Profit for the period</b>	<b>69,448,626</b>	<b>14,666,195</b>	<b>6,025,607</b>	<b>13,085,914</b>	<b>127,507</b>	<b>39,241</b>	<b>(194,993)</b>	<b>10,916,293</b>	<b>(9,059,559)</b>	<b>(1,453,353)</b>	<b>-</b>	<b>(1,179,126)</b>	<b>102,422,352</b>		
Other Items															
Capital expenditure	9,523,630	29,015,828	3,548,202	7,788,676	72,030	38,199	-	290,943	2,017,719	2,676,353	-	-	54,971,580		
Fixed assets depreciation	8,461,420	6,284,757	4,321,564	5,119,234	38,889	654	-	821,591	3,237,776	1,116,343	-	2,143,879	31,546,107		

**CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES**

**Notes to the consolidated interim financial statements - For the three months period ended 31 March 2022**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

**Segment reporting (continued)**

Below is a summary of each segment, which is presented for the year ended 31 December 2021 for each segment:

Statement of financial position	Cleopatra Hospital Company	Cairo Specialised Hospital	Nile Badrawi Hospital	AlShorouk Hospital	CHG for Medical Services	CHG Pharma for management	CHG for Pharmacies	Queens Hospitals	Al Kateb Hospitals	Bedaya El Gedida for Medical Centers and Hospitals	Consolidation adjustment	Total
Non-current assets	1,460,626,912	294,687,131	253,669,733	237,447,580	49,061,664	3,809,120	-	72,791,123	134,865,621	90,287,957	(637,462,776)	1,959,784,065
Current assets	791,225,113	179,127,975	159,423,841	188,924,507	20,212,049	9,090,455	25,456,940	106,725,556	63,940,470	44,503,263	(115,792,725)	1,472,837,444
<b>Total assets</b>	<b>2,251,852,025</b>	<b>473,815,106</b>	<b>413,093,574</b>	<b>426,372,087</b>	<b>69,273,713</b>	<b>12,899,575</b>	<b>25,456,940</b>	<b>179,516,679</b>	<b>198,806,091</b>	<b>134,791,220</b>	<b>(753,255,501)</b>	<b>3,432,621,509</b>
Current liabilities	241,752,965	138,147,695	84,073,028	87,690,796	88,785,291	15,220,662	911,972	66,870,655	43,577,783	11,362,104	(129,873,561)	648,519,390
Non-current liabilities	38,015,589	13,032,679	22,107,912	23,308,314	48,480,290	4,576,460	-	66,602,710	3,382,956	18,596,421	48,181,673	286,285,004
<b>Total Liabilities</b>	<b>279,768,554</b>	<b>151,180,374</b>	<b>106,180,940</b>	<b>110,999,110</b>	<b>137,265,581</b>	<b>19,797,122</b>	<b>911,972</b>	<b>133,473,365</b>	<b>46,960,739</b>	<b>29,958,525</b>	<b>(81,691,888)</b>	<b>934,804,394</b>
<b>Statement of profit or loss:</b>												
Operating revenue	935,166,243	458,923,126	375,285,656	379,473,301	74,520,431	37,365,554	1,193,771	164,383,486	110,217,897	49,272,776	(36,515,379)	2,549,286,862
Operating costs	(523,192,530)	(308,912,823)	(268,928,355)	(266,151,463)	(63,104,174)	(35,782,687)	-	(77,718,776)	(77,201,230)	(30,030,881)	32,401,297	(1,618,621,622)
<b>Gross profit</b>	<b>411,973,713</b>	<b>150,010,303</b>	<b>106,357,301</b>	<b>113,321,838</b>	<b>11,416,257</b>	<b>1,582,867</b>	<b>1,193,771</b>	<b>86,664,710</b>	<b>33,016,667</b>	<b>19,241,895</b>	<b>(4,114,082)</b>	<b>930,665,240</b>
Other expenses and revenues	(184,257,324)	(86,719,952)	(71,000,261)	(67,987,355)	(21,703,339)	(2,744,419)	(379,696)	(33,963,941)	(21,063,178)	(30,310,011)	136,364	(519,993,112)
<b>Profit for the year</b>	<b>227,716,389</b>	<b>63,290,351</b>	<b>35,357,040</b>	<b>45,334,483</b>	<b>(10,287,082)</b>	<b>(1,161,552)</b>	<b>814,075</b>	<b>52,700,769</b>	<b>11,953,489</b>	<b>(11,068,116)</b>	<b>(3,977,718)</b>	<b>410,672,128</b>
Other Items												
Capital expenditure	57,220,004	131,756,662	36,713,943	21,194,874	581,728	17,430	-	2,830,097	8,004,500	6,277,157	-	264,596,395
Fixed assets depreciation	34,827,246	24,387,131	16,828,440	17,837,994	106,399	1,493	-	3,171,302	3,987,360	4,159,763	8,575,523	113,882,651

**CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES**

**Notes to the consolidated interim financial statements - For the three months period ended 31 March 2022**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

**Segment reporting (continued)**

Below is a summary of each segment, which is presented for the period ended 31 March 2021 for each segment:

	Cleopatra Hospital Company	Cairo Specialised Hospital	Nile Badrawi Hospital	Al Shorouk Hospital	CHG for Medical Services	CHG Pharma for pharmacies management	CHG for Hospitals	Queens Hospitals	Al Kateb Hospitals	Bedaya El Gedida for Medical Centers and Hospitals	Consolidation adjustment	Total
<b>Statement of financial position</b>												
Non-current assets	1,462,276,020	201,095,271	235,133,098	219,280,202	54,763,332	4,326,600	-	78,100,712	125,610,219	94,006,872	(632,173,345)	1,842,418,981
Current assets	623,015,008	194,964,089	174,915,785	161,536,579	16,535,147	19,720,150	25,003,584	73,233,273	61,566,408	37,082,740	(116,422,534)	1,271,150,229
<b>Total assets</b>	<b>2,085,291,028</b>	<b>396,059,360</b>	<b>410,048,883</b>	<b>380,816,781</b>	<b>71,298,479</b>	<b>24,046,750</b>	<b>25,003,584</b>	<b>151,333,985</b>	<b>187,176,627</b>	<b>131,089,612</b>	<b>(748,595,879)</b>	<b>3,113,569,210</b>
Current liabilities	212,932,936	104,567,761	98,351,282	86,954,633	75,505,510	24,291,153	726,644	71,373,507	39,352,238	12,113,045	(129,617,487)	596,551,222
Non-current liabilities	52,191,381	10,195,123	22,813,593	8,729,726	55,594,399	4,837,783	-	70,944,375	3,550,626	7,355,251	49,786,526	285,998,783
<b>Total Liabilities</b>	<b>265,124,317</b>	<b>114,762,884</b>	<b>121,164,875</b>	<b>95,684,359</b>	<b>131,099,909</b>	<b>29,128,936</b>	<b>726,644</b>	<b>142,317,882</b>	<b>42,902,864</b>	<b>19,468,296</b>	<b>(79,830,961)</b>	<b>882,550,005</b>
<b>Statement of profit or loss:</b>												
Operating revenue	220,687,826	111,964,649	99,036,007	90,954,420	17,807,901	8,044,115	740,415	48,556,459	40,953,302	9,835,912	(15,417,834)	633,163,172
Operating costs	(124,061,527)	(76,225,117)	(70,374,967)	(62,363,620)	(14,983,257)	(6,302,252)	-	(21,327,085)	(24,004,078)	(6,268,759)	13,944,891	(391,965,771)
<b>Gross profit</b>	<b>96,626,299</b>	<b>35,739,532</b>	<b>28,661,040</b>	<b>28,590,800</b>	<b>2,824,644</b>	<b>1,741,863</b>	<b>740,415</b>	<b>27,229,374</b>	<b>16,949,224</b>	<b>3,567,153</b>	<b>(1,472,943)</b>	<b>241,197,401</b>
Other expenses and revenues	(44,808,609)	(18,623,894)	(16,642,249)	(17,991,719)	(4,921,287)	(1,088,054)	(194,368)	(11,555,814)	(9,880,692)	(7,846,657)	293,805	(133,259,538)
<b>Profit for the period</b>	<b>51,817,690</b>	<b>17,115,638</b>	<b>12,018,791</b>	<b>10,599,081</b>	<b>(2,096,643)</b>	<b>653,809</b>	<b>546,047</b>	<b>15,673,560</b>	<b>7,068,532</b>	<b>(4,279,504)</b>	<b>(1,179,138)</b>	<b>107,937,863</b>
<b>Other Items</b>												
Capital expenditure	10,451,676	20,926,463	3,021,657	1,313,145	-	-	-	627,115	911,765	5,370,760	-	42,622,581
Fixed assets depreciation	5,946,632	5,989,147	3,880,073	4,364,016	12,798	-	-	743,888	2,918,721	1,006,873	2,143,894	27,006,042

**CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES**

**Notes to the consolidated interim financial statements - For the three months period ended 31 March 2022**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

**4. Fixed assets**

	Lands	Machinery, equipment and devices	Furniture	Buildings	Vehicles	Computers	Projects under construction	Total
<b>At 1 January 2021</b>								
Cost	173,240,262	626,167,940	105,792,062	549,004,858	15,691,737	102,687,785	99,720,766	1,672,305,410
Accumulated depreciation	-	(261,113,137)	(38,054,959)	(114,997,947)	(7,328,973)	(45,614,534)	-	(467,109,550)
<b>Net book value</b>	<b>173,240,262</b>	<b>365,054,803</b>	<b>67,737,103</b>	<b>434,006,911</b>	<b>8,362,764</b>	<b>57,073,251</b>	<b>99,720,766</b>	<b>1,205,195,860</b>
<b>Year ended 31 December 2021</b>								
Opening net book value	173,240,262	365,054,803	67,737,103	434,006,911	8,362,764	57,073,251	99,720,766	1,205,195,860
Additions	-	48,252,892	19,125,873	868,488	4,902,800	24,324,199	167,122,143	264,596,395
Disposals	-	(8,189,448)	(1,349,937)	(106,884)	(76,000)	(11,528)	-	(9,733,797)
Write-off	-	(4,179,426)	(967,569)	-	-	(572,134)	-	(5,719,129)
Transfers from projects under construction	-	12,955,477	12,375,644	108,837,042	-	10,035,925	(144,224,088)	-
Depreciation for the year	-	(51,598,344)	(14,197,713)	(20,513,110)	(2,943,291)	(24,630,193)	-	(113,882,651)
Accumulated depreciation of disposal	-	8,462,378	2,125,592	23,103	76,000	581,671	-	11,268,744
<b>Closing net book value</b>	<b>173,240,262</b>	<b>370,758,332</b>	<b>84,848,993</b>	<b>523,115,550</b>	<b>10,322,273</b>	<b>66,821,191</b>	<b>122,618,821</b>	<b>1,351,725,422</b>
<b>At 31 December 2021</b>								
Cost	173,240,262	675,007,435	134,976,073	658,603,504	20,518,537	136,484,247	122,618,821	1,921,448,879
Accumulated depreciation	-	(304,249,103)	(50,127,080)	(135,487,954)	(10,196,264)	(69,663,056)	-	(569,723,457)
<b>Net book value at the year end</b>	<b>173,240,262</b>	<b>370,758,332</b>	<b>84,848,993</b>	<b>523,115,550</b>	<b>10,322,273</b>	<b>66,821,191</b>	<b>122,618,821</b>	<b>1,351,725,422</b>
<b>At 31 March 2022</b>								
Opening net book value	173,240,262	370,758,332	84,848,993	523,115,550	10,322,273	66,821,191	122,618,821	1,351,725,422
Additions	-	12,997,868	6,273,449	337,856	-	2,104,188	33,258,219	54,971,580
Disposals	-	(4,944,728)	(1,070,545)	(220,000)	-	(181,114)	(86,344)	(6,502,731)
Transfers from projects under construction	-	209,319	426,551	2,298,677	-	-	(2,934,547)	-
Depreciation for the period	-	(13,341,279)	(4,321,701)	(5,589,955)	(1,879,846)	(6,413,326)	-	(31,546,107)
Accumulated depreciation of disposal	-	4,824,989	1,069,196	-	-	177,707	-	6,071,892
<b>Balance at 31 March 2022</b>	<b>173,240,262</b>	<b>370,504,501</b>	<b>87,225,943</b>	<b>519,942,128</b>	<b>8,442,427</b>	<b>62,508,646</b>	<b>152,856,149</b>	<b>1,374,720,056</b>
Cost	173,240,262	683,269,894	140,605,528	661,020,037	20,518,537	138,407,321	152,856,149	1,969,917,728
Accumulated depreciation	-	(312,765,393)	(53,379,585)	(141,077,909)	(12,076,110)	(75,898,675)	-	(595,197,672)
<b>Net book value at the period end</b>	<b>173,240,262</b>	<b>370,504,501</b>	<b>87,225,943</b>	<b>519,942,128</b>	<b>8,442,427</b>	<b>62,508,646</b>	<b>152,856,149</b>	<b>1,374,720,056</b>

## CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 5. Right of use

The right of use represents lease contracts related to buildings, machinery and medical equipment and was measured at a carrying amount as if the standard had been applied since the inception of the lease, however discounted using the borrowing rate to the lessee at the date of application, and it is subsequently amortized over the life of the lease using the straight-line method.

	<b>31 March 2022</b>	<b>31 December 2021</b>
<b>Machinery and equipment</b>		
Beginning balance for the period / year	16,818,578	18,824,508
Additions during the period / year	-	-
Depreciation during the period / year	(523,833)	(2,005,930)
<b>Total – machinery and equipment</b>	<b>16,294,745</b>	<b>16,818,578</b>
<b>Buildings</b>		
Beginning balance for the period / year	157,873,037	-
The impact of the first adoption standard no. 49 "Leases"	-	161,848,949
Adjustments	(3,533,940)	
Additions for the period / year	3,046,507	19,974,500
Depreciation for the period / year	(6,079,722)	(23,950,412)
<b>Total</b>	<b>151,305,882</b>	<b>157,873,037</b>
	<b>167,600,627</b>	<b>174,691,615</b>

Lease payments are discounted using the interest rate implicit in the lease. If this rate cannot be determined, the lessee's borrowing rate is used, which is the rate that the lessee would have to pay to borrow the money needed to obtain an asset of similar value in a similar economic environment with similar terms and conditions. An average interest rate of 11.15% was used. For financing lease contracts for buildings 12.15% and 16.15% for financing lease contracts for medical machinery and equipment

#### 6. Inventories

	<b>31 March 2022</b>	<b>31 December 2021</b>
Medicine inventory	27,194,461	21,709,850
Medical supply inventory	26,349,612	26,439,233
Maintenance and spare parts inventory	1,682,621	1,647,600
Stationary inventory	1,320,394	1,142,632
Hospitality inventory	1,273,569	655,754
Food and beverage inventory	112,737	175,091
	<b>57,933,394</b>	<b>51,770,160</b>
<b>Less: Impairment of inventory</b>	<b>(488,831)</b>	<b>(468,972)</b>
	<b>57,444,563</b>	<b>51,301,188</b>

**CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES**

**Notes to the interim condensed consolidated financial statements  
For the three months period ended 31 March 2022**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

**Inventories (continued)**

Movement in the provision for inventory is as follows:

	<u>31 March 2022</u>	<u>31 December 2021</u>	<u>31 March 2021</u>
Balance at 1 January	468,972	466,550	466,550
Provisions formed during the period / year	104,860	1,312,118	141,554
Provisions no longer required during the period / year	(24,631)	(1,049,474)	(357,347)
Write-offs during the period / year	(60,370)	(260,222)	-
<b>Balance at the end of the period / year</b>	<b><u>488,831</u></b>	<b><u>468,972</u></b>	<b><u>250,757</u></b>

**7. Deferred tax**

The movement of deferred tax assets / (liabilities) during the period:

	<u>Balance at 1 January 2022 (Liability)</u>	<u>(Expense) income charged during the period</u>	<u>Balance at 31 March 2022 (Liability)</u>
<b>Liabilities</b>			
Fixed assets	(44,281,274)	(457,273)	(44,738,547)
Fixed assets - fair value impact	(38,359,550)	482,373	(37,877,177)
Intangible assets - fair value impact	(9,979,650)	-	(9,979,650)
<b>Total liabilities</b>	<b><u>(92,620,474)</u></b>	<b><u>25,100</u></b>	<b><u>(92,595,374)</u></b>
<b>Assets</b>			
Provision (excluded claims provisions)	3,347,063	(154,720)	3,192,343
Subsidiaries accumulated losses	7,463,572	-	7,463,572
<b>Net deferred tax – Liability</b>	<b><u>(81,809,839)</u></b>	<b><u>(129,620)</u></b>	<b><u>(81,939,459)</u></b>

The movement of deferred tax assets / (liabilities) during the period:

	<u>Balance at 1 January 2021 (Liability)</u>	<u>(Expense) income charged during the year</u>	<u>Balance at 31 December 2021 (Liability)</u>
<b>Liabilities</b>			
Fixed assets	(38,636,541)	(5,644,733)	(44,281,274)
Fixed assets - fair value impact	(40,289,043)	1,929,493	(38,359,550)
Intangible assets - fair value impact	(9,979,650)	-	(9,979,650)
<b>Total liabilities</b>	<b><u>(88,905,234)</u></b>	<b><u>(3,715,240)</u></b>	<b><u>(92,620,474)</u></b>
<b>Assets</b>			
Provision (excluded claims provisions)	3,547,300	(200,237)	3,347,063
Subsidiaries accumulated losses	7,463,572	-	7,463,572
<b>Net deferred tax – Liability</b>	<b><u>(77,894,362)</u></b>	<b><u>(3,915,477)</u></b>	<b><u>(81,809,839)</u></b>



## CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 8. Trade receivables

	31 March 2022	31 December 2021
Due from customers	540,242,991	502,010,165
Income from inpatients	11,102,395	11,153,442
	<u>551,345,386</u>	<u>513,163,607</u>
<b>Less:</b>		
Expected credit losses in the trade receivables balances	(120,041,431)	(129,839,577)
	<u>431,303,955</u>	<u>383,324,030</u>

The income from inpatients comprises of the revenues that have not been billed at the financial position date in exchange for their stay while the procedures of the medical services have not been completed. Such income is calculated net of the amounts collected in advance during the period of their stay.

The Group applies the EAS no. (47) simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables.

The expected loss rates are based on the payment profiles of customers over a period of 36 month before each financial position date and the corresponding historical credit losses experienced within this period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables. The Group has identified the GDP and the unemployment rate of the countries in which it sells services to be the most relevant factors, and accordingly adjusts the historical loss rates based on expected changes in these factors.

The credit loss allowance for trade receivables is determined according to the provision matrix presented in the table below. The provision matrix is based on the number of days that an asset is past due, with adjusting it.

	31 March 2022			
	Loss Rate	Gross carrying amount	Lifetime ECL	Net carrying value
<b>Trade receivables</b>				
- Current until less than 30 days overdue	1%	352,134,836	1,618,641	350,516,195
- 31 to 60 days overdue	4%	35,548,195	1,523,135	34,025,060
- 61 to 90 days overdue	9%	18,807,900	1,631,977	17,175,923
- 91 to 120 days overdue	17%	11,820,932	1,989,608	9,831,324
- 121 to 360 days overdue	45%	26,994,598	12,257,929	14,736,669
- 361 to 720 days overdue	65%	14,540,190	9,521,406	5,018,784
- More than 720 days	100%	91,498,735	91,498,735	-
<b>Total</b>		<u>551,345,386</u>	<u>120,041,431</u>	<u>431,303,955</u>

**CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES**

**Notes to the interim condensed consolidated financial statements  
For the three months period ended 31 March 2022**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

**Trade receivables (continued)**

	31 December 2021			
	Loss Rate	Gross carrying amount	Lifetime ECL	Net carrying value
<b>Trade receivables</b>				
- Current until less than 30 days overdue	1%	313,356,068	1,970,326	311,385,742
- 31 to 60 days overdue	5%	34,286,882	1,747,469	32,539,413
- 61 to 90 days overdue	11%	18,700,626	2,027,866	16,672,760
- 91 to 120 days overdue	23%	9,174,368	2,114,843	7,059,525
- 121 to 360 days overdue	57%	28,980,899	16,485,495	12,495,404
- 361 to 720 days overdue	70%	10,477,794	7,306,608	3,171,186
- More than 720 days	100%	98,186,970	98,186,970	-
<b>Total</b>		<b>513,163,607</b>	<b>129,839,577</b>	<b>383,324,030</b>

Movement in the provision for trade receivables impairments is as follows:

	31 March 2022	31 December 2021	31 March 2021
Balance at the beginning of the period / year	129,839,577	125,326,367	125,326,367
The impact of the first adoption standard no.47 "Financial Instruments"	-	11,289,842	11,289,842
Provisions formed during the period / year	13,641,472	105,383,023	29,798,437
Provision used during the period / year	(20,053,582)	(52,753,994)	-
Provision no longer required during period / year	(3,386,036)	(59,405,661)	(16,646,348)
<b>Ending balance at the end of period / year</b>	<b>120,041,431</b>	<b>129,839,577</b>	<b>149,768,298</b>

**9. Related parties Transactions:**

During the period / year the Group made transactions with certain related parties. The Balances with related parties at the financial statements date as well as the transactions during the period / year were as follows:

Balances of financial position

(Related parties)	Nature of transaction	Balance due from / (to) related parties 31 March 2022	Balance due from / (to) related parties 31 December 2021
Other parties	Expenses paid on behalf of the Company	802,149	530,300
		<b>802,149</b>	<b>530,300</b>

**CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES**

**Notes to the interim condensed consolidated financial statements  
For the three months period ended 31 March 2022**

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

**10. Debtors and other debit balances**

	<b>31 March 2022</b>	<b>31 December 2021</b>
Advances to suppliers	65,556,945	67,780,202
Prepaid expenses	17,443,756	7,592,208
Withholding taxes	14,695,390	11,494,414
Deposits with others	5,125,924	5,105,318
Employee's custodies	1,017,372	648,595
Accrued income	433,120	421,907
Treasury shares debtors	-	84,428,630
Other debtors	14,062,334	14,233,929
	<b>118,334,841</b>	<b>191,705,203</b>
<b>Less: Impairment of other debit balances</b>	<b>(2,784)</b>	<b>(2,784)</b>
	<b>118,332,057</b>	<b>191,702,419</b>

The movement of the debtor's impairment during the period / year is as follows:

	<b>31 March 2022</b>	<b>31 December 2021</b>	<b>31 March 2021</b>
Balance at the beginning of the period / year	2,784	42,202	42,202
No longer required of the period / year	-	(39,418)	-
<b>Balance at the end of the period / year</b>	<b>2,784</b>	<b>2,784</b>	<b>42,202</b>

**11. Financial assets at amortized cost - Treasury bills**

	<b>31 March 2022</b>	<b>31 December 2021</b>
Treasury Bills (Maturity 61 days)	109,150,000	636,400,000
Treasury bills (Maturity 91 days)	-	45,450,070
Treasury bills (Maturity 30 days)	385,400,000	-
<b>Less: Unearned revenue</b>	<b>(2,227,786)</b>	<b>(4,777,156)</b>
	<b>492,322,214</b>	<b>677,072,914</b>

Treasury bills are entitled to a constant annual return of 8.4% and 9.04% after taxes on 31 March 2022 (31 December: 8.4% and 9.6%).

## CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 12. Cash on hand and at banks

	31 March 2022	31 December 2021
Current accounts	193,113,696	151,913,259
Time deposit	20,963,047	15,036,965
Cash on hand	2,824,683	3,501,864
<b>Less:</b>		
Cash and cash equivalents impairment	(1,336,093)	(1,545,495)
	<b>215,565,333</b>	<b>168,906,593</b>

The movement in the impairment of cash and cash equivalents is as follows:

	31 March 2022	31 December 2021	31 March 2021
Balance at the beginning of the period / year	1,545,489	-	-
The impact of the first adoption standard no.47 "Financial Instruments"	-	4,492,746	4,492,746
Provisions formed during the period / year	408,640	246,880	-
Provision no longer required during period / year	(618,036)	(3,194,131)	(1,324,859)
<b>Ending balance at the end of period / year</b>	<b>1,336,093</b>	<b>1,545,495</b>	<b>3,167,887</b>

The time deposits item includes an amount EGP 20,963,047 at 31 March 2022 (2021: EGP 15,036,965) are denominated in local banks in US dollars and are payable within one from the date of deposit and are subject to a fixed annual return of 0.75%.

Current accounts deposited in Egyptian Pounds are subject to a fixed annual rate of 6% to 6.5% (31 December 2021: from 6 to 6.5%).

For the purpose of preparation of the cash flow statements, cash and cash equivalents consist of:

	31 March 2022	31 March 2021
Cash and bank balances before deducting the expected credit losses	216,901,426	347,948,922
Treasury bills with maturities of 3 months or less	492,322,214	332,829,684
<b>Total</b>	<b>709,223,640</b>	<b>680,778,606</b>

(A) Classification within cash and cash equivalent

Time deposits held at banks presented as cash and cash equivalents if they are due for a period of three months or less from the date of deposit and are repayable with a notice of 24 hours without loss of interest. Treasury bills under cash and cash equivalents have original maturities of no more than three months from the date of acquisition, are easily convertible into known amounts of cash and are subject to an insignificant risk of changes in value.

The Company's cash and bank balances are held with reputable financial institutions with credit ratings from Moody's and Standard & Poor's from B to B2.

(B) Treasury bills

Investment in treasury bills with a maturity period of one to two months.

## CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 13. Non-controlling interests

	Capital	Reserves	Retained earnings	NCI share in acquisition adjustments	Total
<b>Balance at 31 December 2020</b>	34,074,639	7,984,596	65,546,116	120,184	107,725,535
Effect of changes in accounting standards	-	-	(8,945,528)	-	(8,945,528)
<b>Balance at 1 January 2021</b>	34,074,639	7,984,596	56,600,588	120,184	98,780,007
Employee profit share	-	-	(2,197,732)	-	(2,197,732)
Legal reserve	-	732,813	-	-	732,813
Comprehensive income for the year	-	-	23,426,977	-	23,426,977
<b>Balance at 31 December 2021</b>	<b>34,074,639</b>	<b>8,717,409</b>	<b>77,829,833</b>	<b>120,184</b>	<b>120,742,065</b>
<b>Balance at 1 January 2022</b>	34,074,639	8,717,409	77,829,833	120,184	120,742,065
Comprehensive income for the period	-	-	6,439,421	-	6,439,421
<b>Balance at 31 March 2022</b>	<b>34,074,639</b>	<b>8,717,409</b>	<b>84,269,254</b>	<b>120,184</b>	<b>127,181,486</b>

#### 14. Lease liabilities

The lease liabilities represent the present value of the lease obligations related to medical equipment that one of the group companies obtained in exchange for lease contracts for buildings, and it was measured at the present value of the contractual lease payments discounted at an implied rate of return of 12.15%, 16.65% and 11.15%.

	31 March 2022	31 December 2021
<b>The undiscounted value of the lease obligations as follows:</b>		
During the period / year	40,708,003	40,045,267
More than a year	334,874,694	345,574,165
	<b>375,582,697</b>	<b>385,619,432</b>
<b>The present value of the lease obligations as follows:</b>		
During the period / year	40,599,053	38,742,917
More than a year	168,649,746	172,715,165
<b>Balance</b>	<b>209,248,799</b>	<b>211,458,082</b>

## CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### Lease liabilities (continued)

	<b>31 March 2022</b>	<b>31 December 2021</b>
Lease liabilities shown as at 31 December 2021	211,458,082	13,275,078
The impact of the first adoption standard no. 49 "Lease contracts"	-	197,425,332
Adjustments during the period / year	(1,974,536)	-
Additions during the period / year	2,746,507	19,974,500
<b>Lease liabilities at 1 January 2022</b>	<b>212,230,053</b>	<b>230,674,910</b>
<b>Add:</b> Interest formed during the period / year	6,515,132	24,506,126
<b>Deduct:</b> Payments during the period / year	(9,496,386)	(43,722,954)
<b>Lease liabilities at 31 March 2022</b>	<b>209,248,799</b>	<b>211,458,082</b>

#### 15. Bank's overdraft

The group obtained total credit limits in the form of overdrafts from banks in order to finance working capital at an interest rate of 0.1% in addition to the announced borrowing rate from the Central Bank. The total available credit limits amounted to 280 million EGP and the withdrawn value of these credit limits on 31 March 2022 equals nil EGP (31 December 2021: 60,627,560).

#### 16. Trade and other payables

	<b>31 March 2022</b>	<b>31 December 2021</b>
Suppliers and notes payable	224,872,978	227,368,417
Accrued expenses	187,452,340	173,697,850
Social insurance	7,305,101	5,787,212
Employee dividends payable	3,925,487	3,925,487
Other creditors	52,614,068	50,253,593
	<b>476,169,974</b>	<b>461,032,559</b>

## CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 17. Operating revenue

	<u>31 March 2022</u>	<u>31 March 2021</u>
Accommodation and medical supervision revenue	143,536,500	171,429,789
Surgeries revenue	121,018,440	109,896,662
Laboratories revenue	74,808,447	74,624,748
Outpatient clinics revenue	71,015,249	63,030,671
Cardiac catheterization revenue	47,829,325	49,894,346
Radiology revenue	45,491,419	50,097,504
Service charge revenue	45,053,634	43,773,480
Pharmacy revenue	33,383,424	24,571,332
Emergency revenue	20,921,114	18,423,476
Revenues of oncology centre	10,396,911	9,101,445
Endoscopy revenues	5,857,351	3,803,375
Physiotherapy revenue	5,629,808	4,902,803
Cardiac tests revenue	4,516,293	3,636,623
Dentistry revenue	4,294,129	1,979,604
Other departments revenues	3,153,341	3,997,314
	<u><b>636,905,385</b></u>	<u><b>633,163,172</b></u>

All types of revenue are recognized at the revenue recognition point in time.

#### 18. Operating costs

	<u>31 March 2022</u>	<u>31 March 2021</u>
Medical and pharmaceutical supplies	121,082,262	128,076,387
Salaries, wages and benefits	112,394,963	102,348,518
Doctors' fees	104,651,425	95,145,361
Fixed assets depreciation	23,869,130	22,205,122
Maintenance, spare parts and energy expenses	18,700,806	16,274,001
Consumables costs	11,457,815	10,971,525
Services from others	8,490,384	8,528,260
Leased assets depreciation	5,035,465	4,528,509
Rents	2,591,385	1,675,133
Other expenses	6,680,706	2,212,955
	<u><b>414,954,341</b></u>	<u><b>391,965,771</b></u>

## CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

#### 19. General and administrative expenses

	<u>31 March 2022</u>	<u>31 March 2021</u>
Salaries, wages and benefits	47,987,346	41,465,093
Fixed assets depreciation	7,676,975	4,800,920
Professional and consulting fees	5,893,001	6,971,313
Maintenance, spare parts and energy expenses	4,674,236	2,907,898
Services from others	4,648,534	4,461,105
Program expenses	4,195,508	3,620,406
Intangible assets amortization	3,972,321	3,972,321
Right of use assets depreciation	1,568,090	1,664,167
Consumables costs	592,293	563,622
Other expenses	10,817,412	11,327,892
	<u><b>92,025,716</b></u>	<u><b>81,754,737</b></u>

#### 20. Impairment of financial assets

	<u>31 March 2022</u>	<u>31 March 2021</u>
Impairment in trade receivables	10,255,436	13,152,089
Impairment in cash at banks	(209,396)	(1,324,859)
	<u><b>10,046,040</b></u>	<u><b>11,827,230</b></u>

#### 21. Earnings per share (basic / diluted)

The basic earnings per share is calculated by dividing the net profit for the period by the number of shares outstanding during the period.

	<u>31 March 2022</u>	<u>31 March 2021</u>
Net profit	102,422,352	107,937,863
Non-controlling interest	(6,439,421)	(6,628,950)
<b>Distributable net profit</b>	<u><b>95,982,931</b></u>	<u><b>101,308,913</b></u>
Number of shares issued and paid	1,532,511,712	1,600,000,000
<b>Earnings per share of the shareholders' share in the net profit for the period (basic / diluted )</b>	<u><b>0.06</b></u>	<u><b>0,06</b></u>

#### 22. Commitments

##### Capital commitments:

Capital commitments at financial period end, which are not yet due, amounted to EGP 345,154,528 (31 December 2021: EGP 141,285,345).



## CLEOPATRA HOSPITAL COMPANY "S.A.E." AND ITS SUBSIDIARIES

### Notes to the interim condensed consolidated financial statements For the three months period ended 31 March 2022

(All amounts in the notes are shown in Egyptian Pounds unless otherwise stated)

---

#### 23. Treasury shares

On February 24, 2022, the board of directors unanimously agreed that the company would purchase treasury shares from the stock market, and the purchase would be on the price of the security during the trading sessions. It was also unanimously agreed that the financing of the purchase process would be self-financing from the company's resources, and that purchase would take place from the session on February 27, 2022, until the implementation of the purchase of treasury shares amounting to a maximum of 10% of the company's total shares, without the participation of any of the main shareholders or Internal and their associated groups in accordance with the law.

Based on the decision of the Board of Directors, the group purchased 67,488,288 shares of its shares from the stock market for a total amount of 234,816,315 Egyptian pounds, and it was offered by deduction from the equity of treasury shares.

#### 24. Significant and subsequent events

On 13 February 2020, the Cleopatra Hospital Company, the General Authority for River Transport, the Nile Badrawi Hospital Company and the heirs of Eng. Hassan Badrawi signed a comprehensive and final settlement agreement, according to which it was agreed to resolve, settle and end all disputes and claims related to the land on which Nile Badrawi Hospital was built. The total settlement amounted to EGP 36 million, bearing in mind that part of the settlement falls within the limits of the amounts deducted from the sale price of the shares of Nile Badrawi Hospital in favor of Cleopatra Hospital, and it was agreed to waive between the General Authority for River Transport and the Nile Badrawi Hospital Company for the disputes raised by each of them. Regarding the land being settled. On 31 March 31 2021, the Administrative Court issued a ruling accepting the case in form and rejecting it in substance. The Cairo Governorate and the Nile Badrawi Hospital Company appealed the aforementioned ruling before the Supreme Administrative Court, and a court hearing was set for 21 June 2022, until both parties submit the settled settlement contracts between the parties.

On 29 December 2021, the Board of Directors agreed to sign an agreement to complete the construction, management and operation of a medical facility (Sky Hospital) for a period of 27 years, located in the Fifth Settlement area and owned by: Housing and Social Services Fund for Workers in the Petroleum Sector / Egyptian Natural Gas Company (GASCO) LLC/ The Egyptian Company for the Distribution of Natural Gas for Cities (Town Gas) "SAE" affiliated with the General Petroleum Corporation, bearing in mind that the ownership of the hospital will remain for the duration of the contract and after its termination to the current owners. The contract was signed on 30 December 2021. On 3 March 2022, CHG Sky Hospital was established to manage the business of Sky Hospital, with a total authorized capital of 350,000,000 EGP, of which 35,000,000 EGP were paid. And Cleopatra Hospital's shareholding is 99.99%.

The company signed agreements on 5 October 2021, which are conditional on their implementation by several conditions, the most important of which is obtaining the approvals of the Ministry of Health and Population, as part of a deal to complete and equip a hospital building with a capacity of more than 400 beds in the New Cairo area, and the group seeks to complete the deal after obtaining approvals The Ministry of Health and Population, in addition to completing the rest of the preconditions stipulated in the agreements, and on 26 April 2022, the two parties decided to end negotiations to complete the deal, due to the failure to complete the preconditions stipulated in the agreements.